· Regulation · Regulation Desk
A trade Q&A published August 7, 2026 on preparing for FDA inspections of compounded GLP-1 operations signals that enforcement has moved beyond warning letters to on-site inspection, Form 483 observations, and licence risk.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.